SIETES :: 92381 citas

Resultados de la búsqueda por DERMATOLÓGICOS REFINAR BÚSQUEDA

1.

Pottegård A, Pedersen SA, Alba S, Schmidt J, Hölmich LR, Friis S, Gaist D. Association of hydrochlorothiazide use and risk of malignant melanoma. JAMA Intern Med 2018:29 de mayo. [Ref.ID 102645]

2.

Maya Y, Ota M. Drug-induced localised scleroderma. BMJ 2018;360:12 de abril. [Ref.ID 102643]

3.

Tangamornsuksan W, Lohitnavy M. Association between HLA-B*1301 and dapsone-induced cutaneous adverse drug reactions: a systematic review and meta-analysis. JAMA Dermatol 2018;154:1 de abril. [Ref.ID 102558]

4.

Imatoh T, Sai K, Fukasawa C, Hinomura Y, Nakamura R, Okamoto-Uchida Y, Segawa K, Saito Y. Association between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database. Eur J Clin Pharmacol 2017;73:1643-53. [Ref.ID 102180]

5.

Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]

6.

Anónimo. Fingolimod (Gilenya): nuevas contraindicaciones de uso en pacientes con patología cardiaca subyacente y recomendaciones de revisiones dermatológicas. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:6 de noviembre. [Ref.ID 102124]

7.

Trubiano JA, Adkinson NF, Phillips EJ. Penicillin allergy Is not necessarily forever. JAMA 2017;318:82-3. [Ref.ID 102053]

8.

Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorenzton M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017:11 de septiembre. [Ref.ID 102052]

9.

Hammann F, Gotta V, Conen K, Medinger M, Cesana P, Rochlitz C, Taegtmeyer AB. Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. Br J Clin Pharmacol 2017;83:927-30. [Ref.ID 101972]

10.

Walter SR, Day RO, Gallego B, Westbrook JI. The impact of serious adverse drug reactions: a population-based study of a decade of hospital admissions in New South Wales, Australia. Br J Clin Pharmacol 2017;83:416-26. [Ref.ID 101933]

11.

Ramírez E, Medrano-Casique N, Tong HY, Bellón T, Cabañas R, Fiandor A, González-Ramos J, Herranz P, Trigo E, Muñoz M, Borobia AM, Carcas AJ, Frías J. Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital. Br J Clin Pharmacol 2017;83:400-15. [Ref.ID 101932]

12.

Finch A, Kubler P. The management of gout. Australian Prescriber 2016;39:1 de agosto. [Ref.ID 100572]

13.

Anónimo. FDA approves Differin Gel 0.1% for over-the-counter use to treat acne. FDA U.S. Food and Drug Administration 2016:8 de julio. [Ref.ID 100485]

14.

Anonimo. Zecuity (sumatriptan) migraine patch: Drug Safety Communication - FDA evaluating risk of burns and scars. FDA MedWatch alert 2016:2 de junio. [Ref.ID 100411]

15.

Anónimo. Zecuity (sumatriptan) migraine patch: Drug Safety Communication - FDA evaluating risk of burns and scars. FDA U.S. Food and Drug Administration 2016:2 de junio. [Ref.ID 100357]

16.

Imbernón-Moya A, Chico R, Aguilar-Martínez A. Manifestaciones cutáneas y mucosas asociadas al consumo de cocaína. Med Clin (Barc) 2016;146:544-9. [Ref.ID 100354]

17.

18.

Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NMH, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016;387:40-52. [Ref.ID 99988]

19.

Tsianakas A, Ständer S. Dupilumab: a milestone in the treatment of atopic dermatitis. Lancet 2016;387:4-5. [Ref.ID 99987]

20.

Anónimo. Vemurafenib (Zelboraf): risk of potentiation of radiation toxicity. Drug Safety Update 2015;9:2. [Ref.ID 99642]